glaxo-forms-vaccine-jv-with-chinese-firm

Glaxo forms vaccine JV with Chinese firm

GlaxoSmithKline and Shenzhen Neptunus will create a joint venture to make influenza vaccines for Greater China.

Drug company GlaxoSmithKline GSK has formed a joint venture with Chinese firm Shenzhen Neptunus Interlong Bio-Technique Company to develop and manufacture influenza vaccines for the Chinese market.

The JV will make influenza vaccines for China, Hong Kong and Macau, including vaccines for seasonal, pre-pandemic and pandemic influenza.  

Shenzhen Neptunus will own 60% of the JV and will contribute cash and assets to the tune of approximately $47 million. The Chinese firm will also provide local manufacturing capacity and research and development expertise, and will transfer, sub-license or otherwise make available to the JV proprietary rights and interests in defined influenza vaccines and a rabies vaccine. The parties have agreed that the...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222